iron chelating agents

Summary

Summary: Organic chemicals that form two or more coordination links with an iron ion. Once coordination has occurred, the complex formed is called a chelate. The iron-binding porphyrin group of hemoglobin is an example of a metal chelate found in biological systems.

Top Publications

  1. ncbi Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study
    Ali T Taher
    American University of Beirut, Beirut, Lebanon
    Blood 120:970-7. 2012
  2. ncbi Reduction of iron-regulated amyloid precursor protein and beta-amyloid peptide by (-)-epigallocatechin-3-gallate in cell cultures: implications for iron chelation in Alzheimer's disease
    L Reznichenko
    Eve Topf and US National Parkinson Foundation Centers for Neurodegenerative diseases and Department of Pharmacology, Faculty of Medicine, Technion, Haifa, Israel
    J Neurochem 97:527-36. 2006
  3. ncbi Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia
    Dudley J Pennell
    Royal Brompton Hospital, London SW3 6NP, United Kingdom
    Blood 115:2364-71. 2010
  4. ncbi Clinical trial of deferiprone iron chelation therapy in beta-thalassaemia/haemoglobin E patients in Thailand
    Pensri Pootrakul
    Thalassaemia Research Centre, Institute of Science and Technology for Research and Development, Mahidol University, Salaya Campus, Salaya, UK
    Br J Haematol 122:305-10. 2003
  5. ncbi Iron chelation improves endothelial function in patients with coronary artery disease
    S J Duffy
    Evans Department of Medicine and Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, MA, USA
    Circulation 103:2799-804. 2001
  6. ncbi Maculas affected by age-related macular degeneration contain increased chelatable iron in the retinal pigment epithelium and Bruch's membrane
    Paul Hahn
    F M Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Philadelphia, PA 19104, USA
    Arch Ophthalmol 121:1099-105. 2003
  7. ncbi Chelating agents for the treatment of systemic iron overload
    Y Ma
    Institute of Pharmaceutical Science, King s College London, Franklin Wilkins Building, 150 Stamford Street, London, SE1 9NH, UK
    Curr Med Chem 19:2816-27. 2012
  8. ncbi Iron overload in non-transfusion-dependent thalassemia: a clinical perspective
    Khaled M Musallam
    IRCCS Cà Granda Foundation Maggiore Policlinico Hospital, University of Milan, Milan, Italy
    Blood Rev 26:S16-9. 2012
  9. ncbi A fluorescence assay for assessing chelation of intracellular iron in a membrane model system and in mammalian cells
    Z I Cabantchik
    Department of Biological Chemistry, Hebrew University of Jerusalem, Israel
    Anal Biochem 233:221-7. 1996
  10. ncbi Iron overload in thalassaemia intermedia: reassessment of iron chelation strategies
    Ali Taher
    Department of Internal Medicine, Haematology Oncology Division, American University of Beirut, Medical Centre, Beirut, Lebanon
    Br J Haematol 147:634-40. 2009

Research Grants

  1. Hepcidin Replacement Therapy for Iron Overload Disorders
    James W Larrick; Fiscal Year: 2013
  2. IRON CHELATORS PREDICATED ON DESFERRITHIOCIN
    RAYMOND JOSEPH BERGERON; Fiscal Year: 2013
  3. CULTURED CARDIAC MYOCYTES--A MODEL OF IRON OVERLOAD
    Chaim Hershko; Fiscal Year: 1991
  4. ACCELERATING IRON CHELATION FROM SERUM TRANSFERRIN
    WESLEY HARRIS; Fiscal Year: 2004
  5. MICROBIAL IRON TRANSPORT
    BENJAMIN BYERS; Fiscal Year: 1980
  6. CARDIOMYOPATHY OF IRON OVERLOAD--FIRST ANIMAL MODEL
    George Miller; Fiscal Year: 1992
  7. DESIGN AND CLINICAL ASSESSMENT OF PYRIDINONE CHELATORS
    Robert Hider; Fiscal Year: 1992
  8. THALASSEMIAS, HEMOGLOBINOPATHIES AND RELATED PROBLEMS
    Prawase Wasi; Fiscal Year: 1991
  9. MODELING OF MIXED LIGAND THERAPY FOR IRON OVERLOAD
    Robert Hider; Fiscal Year: 2002
  10. Cardiac Function and Cardiac iron (T2*) in Thalassemia
    John Wood; Fiscal Year: 2007

Detail Information

Publications262 found, 100 shown here

  1. ncbi Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study
    Ali T Taher
    American University of Beirut, Beirut, Lebanon
    Blood 120:970-7. 2012
    ..8%), and diarrhea (n = 6; 3.6%). This is the first randomized study showing that iron chelation with deferasirox significantly reduces iron overload in NTDT patients with a frequency of overall adverse events similar to placebo...
  2. ncbi Reduction of iron-regulated amyloid precursor protein and beta-amyloid peptide by (-)-epigallocatechin-3-gallate in cell cultures: implications for iron chelation in Alzheimer's disease
    L Reznichenko
    Eve Topf and US National Parkinson Foundation Centers for Neurodegenerative diseases and Department of Pharmacology, Faculty of Medicine, Technion, Haifa, Israel
    J Neurochem 97:527-36. 2006
    ..Thus, the natural non-toxic brain-permeable EGCG may provide a potential therapeutic approach for AD and other iron-associated disorders...
  3. ncbi Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia
    Dudley J Pennell
    Royal Brompton Hospital, London SW3 6NP, United Kingdom
    Blood 115:2364-71. 2010
    ..7%) to 69.6 (+/- 4.5%) (+1.8%; P < .001). This prospective study shows that deferasirox is effective in removing and preventing myocardial iron accumulation. This study is registered at http://clinicaltrials.gov as NCT00171821...
  4. ncbi Clinical trial of deferiprone iron chelation therapy in beta-thalassaemia/haemoglobin E patients in Thailand
    Pensri Pootrakul
    Thalassaemia Research Centre, Institute of Science and Technology for Research and Development, Mahidol University, Salaya Campus, Salaya, UK
    Br J Haematol 122:305-10. 2003
    ..Further studies are needed to determine the optimum dose and length of treatment needed to reduce iron burden to a safe level in these patients...
  5. ncbi Iron chelation improves endothelial function in patients with coronary artery disease
    S J Duffy
    Evans Department of Medicine and Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, MA, USA
    Circulation 103:2799-804. 2001
    ..These results suggest that iron availability contributes to impaired nitric oxide action in atherosclerosis...
  6. ncbi Maculas affected by age-related macular degeneration contain increased chelatable iron in the retinal pigment epithelium and Bruch's membrane
    Paul Hahn
    F M Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Philadelphia, PA 19104, USA
    Arch Ophthalmol 121:1099-105. 2003
    ..To investigate whether iron is involved in the pathogenesis of age-related macular degeneration (AMD)...
  7. ncbi Chelating agents for the treatment of systemic iron overload
    Y Ma
    Institute of Pharmaceutical Science, King s College London, Franklin Wilkins Building, 150 Stamford Street, London, SE1 9NH, UK
    Curr Med Chem 19:2816-27. 2012
    ..This newly emerging range of iron chelators will enable clinicians to apply iron chelation methodology to other disease states and to begin to design personalised chelation regimes...
  8. ncbi Iron overload in non-transfusion-dependent thalassemia: a clinical perspective
    Khaled M Musallam
    IRCCS Cà Granda Foundation Maggiore Policlinico Hospital, University of Milan, Milan, Italy
    Blood Rev 26:S16-9. 2012
    ..Therefore, direct measurement of LIC is recommended with chelation therapy as indicated...
  9. ncbi A fluorescence assay for assessing chelation of intracellular iron in a membrane model system and in mammalian cells
    Z I Cabantchik
    Department of Biological Chemistry, Hebrew University of Jerusalem, Israel
    Anal Biochem 233:221-7. 1996
    ..They are also potentially applicable to chelation of other metals such as Co(II), Ni(II), and Cu(II) and to any cellular system or membrane vesicles...
  10. ncbi Iron overload in thalassaemia intermedia: reassessment of iron chelation strategies
    Ali Taher
    Department of Internal Medicine, Haematology Oncology Division, American University of Beirut, Medical Centre, Beirut, Lebanon
    Br J Haematol 147:634-40. 2009
    ..Better understanding of the need to assess and treat iron overload in both transfused and non-transfused TI patients is clearly required...
  11. ncbi The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: The mechanisms involved in inhibiting cell-cycle progression
    J Gao
    Iron Metabolism and Chelation Group, The Heart Research Institute, 145 Missenden Road, Camperdown, Sydney, New South Wales, 2050 Australia
    Blood 98:842-50. 2001
    ..Failure to translate these cell-cycle inhibitors may contribute to dysregulation of the cell cycle after exposure to chelators. (Blood. 2001;98:842-850)..
  12. ncbi Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up
    M Domenica Cappellini
    Universita di Milano, Ca Granda Foundation Istituto di Ricovero e Cura a Carattere Scientifico corrected IRCCS, Milan, Italy
    Blood 118:884-93. 2011
    ..This trial was registered at www.clinicaltrials.gov as #NCT00171210...
  13. pmc Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload
    Ali Taher
    Department of Internal Medicine, Haematology Oncology Division, American University of Beirut, Medical Centre, Beirut, Lebanon
    Br J Haematol 147:752-9. 2009
    ..This has important implications for patients who are heavily transfused and may require higher doses to reduce body iron burden...
  14. ncbi Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion
    Dong Fu
    Iron Metabolism and Chelation Program, Department of Pathology, University of Sydney, New South Wales, Australia
    Blood 110:752-61. 2007
    ..These results are important for considering the mechanism of Fe depletion-mediated cell-cycle arrest and apoptosis and the efficacy of chelators as antitumor agents...
  15. ncbi In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals
    L M Sayre
    Department of Chemistry, Case Western Reserve University, Cleveland, Ohio 44106, USA
    J Neurochem 74:270-9. 2000
    ....
  16. ncbi Artemisinins target the SERCA of Plasmodium falciparum
    U Eckstein-Ludwig
    Department of Cellular and Molecular Medicine, St George s Hospital Medical School, Cranmer Terrace, London SW17 0RE, UK
    Nature 424:957-61. 2003
    ..Fluorescent artemisinin labels parasites similarly and irreversibly in an Fe2+-dependent manner. These data provide compelling evidence that artemisinins act by inhibiting PfATP6 outside the food vacuole after activation by iron...
  17. pmc Specific iron chelators determine the route of ferritin degradation
    Ivana De Domenico
    Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT 84132, USA
    Blood 114:4546-51. 2009
    ..These results indicate that ferritin degradation occurs by 2 routes: a DFO-induced entry of ferritin into lysosomes and a cytosolic route in which iron is extracted from ferritin before degradation by the proteasome...
  18. ncbi Dysregulation of iron homeostasis in the CNS contributes to disease progression in a mouse model of amyotrophic lateral sclerosis
    Suh Young Jeong
    Centre for Research in Neuroscience, The Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
    J Neurosci 29:610-9. 2009
    ..These data suggest that iron chelator therapy might be useful for the treatment of ALS...
  19. ncbi A review of fluorescence methods for assessing labile iron in cells and biological fluids
    Breno P Esposito
    Department of Biological Chemistry, Hebrew University of Jerusalem, Jerusalem, 91904, Israel
    Anal Biochem 304:1-18. 2002
    ..The main focus of the review is on the design and application of fluorescent probes as analytical tools for assessing labile iron and iron transport mechanisms and the efficiency of iron chelators in solution and in cellular systems...
  20. ncbi Antioxidant activity of sulfated polysaccharide fractions extracted from Undaria pinnitafida in vitro
    Tingting Hu
    School of Life Sciences, Anhui University, Feixi Street, Hefei 230039, PR China
    Int J Biol Macromol 46:193-8. 2010
    ..Available data obtained by in vitro models suggested that the correlation between the sulfate content and antioxidant activity was positive...
  21. ncbi Linear growth in homozygous beta-thalassemia and beta-thalassemia/hemoglobin E patients under different treatment regimens
    V Viprakasit
    Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
    J Med Assoc Thai 84:929-41. 2001
    ..However, adequate iron chelation and hormonal treatment in these patients were also required in order to achieve normal adult height...
  22. pmc Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging
    Alessia Pepe
    Magnetic Resonance Imaging Unit, Fondazione G Monasterio, C N R Regione Toscana, Pisa, Italy
    Haematologica 96:41-7. 2011
    ....
  23. ncbi Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia
    Vassilis Ladis
    First Department of Paediatrics, Athens University, Thalassaemia Unit, Aghia Sofia Children s Hospital Encephalos Euromedica Laboratories, Rizariou 3, Halandri, Athens Greece
    Br J Haematol 151:504-8. 2010
    ..This small-scale study indicated that deferasirox may be suitable for controlling iron levels in patients with thalassaemia intermedia...
  24. pmc Treatment of classic pantothenate kinase-associated neurodegeneration with deferiprone and intrathecal baclofen
    Napala R Pratini
    Pediatric Clinical Research Center, Children s Hospital and Research Center, Oakland, California 94609, USA
    Am J Phys Med Rehabil 92:728-33. 2013
    ..Although treatment with deferiprone alone was not attempted, this combination therapy seems to be more efficacious than treatment with only intrathecal baclofen. ..
  25. ncbi Optimal management of β thalassaemia intermedia
    Ali T Taher
    Department of Internal Medicine, Division of Haematology and Oncology, American University of Beirut Medical Centre, Riad El Solh 1107 2020, Beirut, Lebanon
    Br J Haematol 152:512-23. 2011
    ..Until solid evidence-based guidelines are available, individualised treatment should be entertained...
  26. ncbi Effect of iron overload and iron-chelating therapy on allogeneic hematopoietic SCT in children
    J W Lee
    Department of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Republic of Korea
    Bone Marrow Transplant 44:793-7. 2009
    ..Elevated serum ferritin level was associated with increased TRM and decreased survival, and the analysis of the IC group suggested the benefit of iron-chelating therapy to improve the outcome of HSCT...
  27. ncbi Flow cytometry measurement of the labile iron pool in human hematopoietic cells
    Eugenia Prus
    Department of Hematology, Hadassah Hebrew University Medical Center, Jerusalem, Israel
    Cytometry A 73:22-7. 2008
    ..The results also showed that among myeloid precursors, LIP increases along cell maturation. Flow cytometry might be useful for evaluating LIP in various diseases and for studying the efficacy of iron-chelators...
  28. ncbi Longitudinal changes in serum ferritin levels correlate with measures of hepatic stiffness in transfusion-independent patients with β-thalassemia intermedia
    Khaled M Musallam
    Department of Medicine and Medical Specialties, IRCCS Cà Granda Foundation Maggiore Policlinico Hospital, University of Milan, Milan, Italy
    Blood Cells Mol Dis 49:136-9. 2012
    ..836, p<0.001) noted in both non-chelated and chelated patients. An association between iron overload status and hepatic disease merits further evaluation in this subset of transfusion-independent patients...
  29. pmc The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial
    Brad Spellberg
    Division of General Internal Medicine, Los Angeles Biomedical Research Institute, Harbor University of California Los Angeles UCLA Medical Center, Torrance, CA, USA
    J Antimicrob Chemother 67:715-22. 2012
    ..To determine the safety of combination deferasirox plus LAmB therapy for mucormycosis, a multicentred, placebo-controlled, double-blinded clinical trial was conducted...
  30. ncbi Treatment strategies for hemoglobin E beta-thalassemia
    Nancy F Olivieri
    Toronto General Hospital, Toronto, Ontario, Canada
    Blood Rev 26:S28-30. 2012
    ..Therefore, periodic reassessment of the need for transfusion therapy is recommended, and intermittent transfusion therapy may now be explored as an approach in this disorder...
  31. ncbi Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1)
    Y Rombos
    First Dept of Medicine, Athens University Medical School, Laikon Hospital, 11527 Athens, Greece
    Haematologica 85:115-7. 2000
    ..Deferiprone (1,2-dimethyl-3-hydroxy-pyridine-4-one, L1) is an orally active iron chelator mainly excreted via urine. We conducted a study in order to determine the efficacy and safety of L1 in Greek thalassemic patients...
  32. pmc β-thalassemia intermedia: a clinical perspective
    Khaled M Musallam
    Department of Medicine and Medical Specialties, IRCCS Cà Granda Foundation Maggiore Policlinico Hospital, 20122 Milan, Italy
    Cold Spring Harb Perspect Med 2:a013482. 2012
    ..The effects of some therapeutic interventions on the development of clinical complications are also discussed...
  33. ncbi Iron chelation treatment with deferasirox prior to high-dose chemotherapy and autologous stem cell transplantation may reduce the risk of hepatic veno-occlusive disease in children with high-risk solid tumors
    Hee Won Chueh
    Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon dong, Gangnam Gu, Seoul, Republic of Korea
    Pediatr Blood Cancer 58:441-7. 2012
    ....
  34. ncbi Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes
    Michel Delforge
    Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Herestraat 49, 3000, Leuven, Belgium
    Ann Hematol 90:655-66. 2011
    ..Prospective randomized trials are necessary to establish causally the efficacy of iron chelation therapy in MDS...
  35. pmc Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease
    Elliott Vichinsky
    Children s Hospital and Research Center at Oakland, Oakland, CA 94609, USA
    Br J Haematol 154:387-97. 2011
    ..Iron burden was substantially reduced with appropriate dosing in patients treated for at least 4 years...
  36. ncbi The iron chelator pyridoxal isonicotinoyl hydrazone (PIH) protects plasmid pUC-18 DNA against *OH-mediated strand breaks
    M Hermes-Lima
    Departamento de Biologia Celular, Universidade de Brasilia, DF, Brazil
    Free Radic Biol Med 25:875-80. 1998
    ..Since we observed that PIH enhances the Fe(II) autoxidation rate, measured by the ferrozine technique, PIH may limit *OH formation and consequently DNA damage by decreasing the amount of Fe(II) available to catalyze Fenton reactions...
  37. ncbi Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases
    Hailin Zheng
    Department of Organic Chemistry and Neurobiology, The Weizmann Institute of Science, Rehovot 76100, Israel
    Bioorg Med Chem 13:773-83. 2005
    ..EPR studies suggested that Chelator 9 also act as radical scavenger to directly scavenge hydroxyl radical...
  38. ncbi The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores
    John C Wood
    Children s Hospital of Los Angeles, 4650 Sunset Blvd, Los Angeles, CA 90027, USA
    Blood 116:537-43. 2010
    ..Monotherapy with deferasirox was effective in patients with mild to moderate iron stores but failed to remove cardiac iron in patients with severe hepatic iron burdens. This study was registered at www.clinicaltrials.gov as #NCT00447694...
  39. pmc Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload
    Dudley J Pennell
    Royal Brompton Hospital, London, UK
    Haematologica 96:48-54. 2011
    ..Since normalization of cardiac T2* takes several years, the efficacy and safety of deferasirox was assessed for two years in patients with β-thalassemia major in the cardiac sub-study of the EPIC trial...
  40. ncbi Effects of deferasirox and deferiprone on cellular iron load in the human hepatoma cell line HepaRG
    Francois Gaboriau
    Inserm U991 EA MDC, Universite de Rennes 1, Hopital Pontchaillou, 35033 Rennes Cedex, France
    Biometals 23:231-45. 2010
    ..In contrast, the effects of CP20 suggest the potential involvement of this compound in the iron uptake from the external medium into the hepatocytes from the HepaRG cell line, therefore acting like a siderophore in this cell model...
  41. ncbi Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells
    Hava Glickstein
    Department of Biological Chemistry, Alexander Silberman Institute of Life Sciences, Hebrew University of Jerusalem, Safra Givat Ram Campus, Jerusalem 91904, Israel
    Blood 106:3242-50. 2005
    ....
  42. ncbi Deferiprone, an orally deliverable iron chelator, ameliorates experimental autoimmune encephalomyelitis
    K M Mitchell
    Department of Molecular and Integrative Physiology, University of Kansas Medical Center, Kansas City, KS 66160, USA
    Mult Scler 13:1118-26. 2007
    ..Deferiprone had no effect on proliferation or viability of cells that were not costimulated. In summary, deferiprone effectively suppressed active EAE disease and it inhibited T-cell function...
  43. pmc The iron chelator, desferrioxamine, reduces inflammation and atherosclerotic lesion development in experimental mice
    Wei Jian Zhang
    Linus Pauling Institute, Oregon State University, Corvallis, OR 97331, USA
    Exp Biol Med (Maywood) 235:633-41. 2010
    ..Whether eliminating excess iron is a useful adjunct for the prevention or treatment of atherosclerosis in humans remains to be investigated...
  44. pmc Nanoparticle and iron chelators as a potential novel Alzheimer therapy
    Gang Liu
    Department of Radiology, University of Utah, Salt Lake City, Utah, USA
    Methods Mol Biol 610:123-44. 2010
    ..This method may provide a safer and more effective means of reducing the metal load in neural tissue, thus attenuating the harmful effects of oxidative damage and its sequelae. Experimental procedures are presented in this chapter...
  45. ncbi Antioxidant and iron-binding properties of curcumin, capsaicin, and S-allylcysteine reduce oxidative stress in rat brain homogenate
    Amichand Dairam
    Department of Biochemistry, Microbiology and Biotechnology and Faculty of Pharmacy, Rhodes University, PO Box 94, Grahamstown, South Africa
    J Agric Food Chem 56:3350-6. 2008
    ....
  46. pmc Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance
    Bernadette Modell
    UCL Centre for Health Informatics and Multiprofessional Education, Holborn Union Building, Whittington Campus, Highgate Hill, London, N19 5LW, UK
    J Cardiovasc Magn Reson 10:42. 2008
    ..A study of survival and causes of death was undertaken which aimed to include the possible impact of T2* cardiovascular magnetic resonance (CMR)...
  47. ncbi Iron overload in MDS-pathophysiology, diagnosis, and complications
    Norbert Gattermann
    Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Mooren Str 5, 40225, Dusseldorf, Germany
    Ann Hematol 90:1-10. 2011
    ....
  48. pmc The iron chelator deferasirox protects mice from mucormycosis through iron starvation
    Ashraf S Ibrahim
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, California 90502, USA
    J Clin Invest 117:2649-57. 2007
    ..As iron availability is integral to the pathogenesis of other infections (e.g., tuberculosis, malaria), broader investigation of deferasirox as an antiinfective treatment is warranted...
  49. ncbi Iron chelation in the biological activity of curcumin
    Yan Jiao
    Department of Cancer Biology, Wake Forest University Health Sciences, Winston Salem, NC 27157, USA
    Free Radic Biol Med 40:1152-60. 2006
    ..These results suggest that iron chelation may be an additional mode of action of curcumin...
  50. ncbi In vitro analysis of iron chelating activity of flavonoids
    Premysl Mladenka
    Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University in Prague, Hradec Kralove, Czech Republic
    J Inorg Biochem 105:693-701. 2011
    ..Isolated keto, hydroxyl, methoxyl groups or an ortho methoxy-hydroxy groups were not associated with iron chelation at all...
  51. ncbi Effectiveness of deferiprone in transfusion-independent beta-thalassemia/HbE patients
    Krittapoom Akrawinthawong
    Department of Biochemistry, Faculty of Medicine, Department of Internal Medicine, Siriraj Hospital, Mahidol University, Thailand
    Hematology 16:113-22. 2011
    ..DFP therapy alone improved iron overload and oxidative stress and compliance was good. We propose that prevention of pulmonary hypertension is also possible for TI undergoing intermittent blood transfusion...
  52. ncbi Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major
    Kallistheni Farmaki
    Transfusion Department and Thalassaemia Unit, General Hospital of Corinth, Leoforos Athinon 53, Corinth 20100, Greece
    Br J Haematol 148:466-75. 2010
    ..These results suggest that intensive combined chelation normalized patients' iron load and thereby prevented and reversed cardiac and multiple endocrine complications associated with transfusion iron overload...
  53. pmc Antifungal activities of natural and synthetic iron chelators alone and in combination with azole and polyene antibiotics against Aspergillus fumigatus
    Kol A Zarember
    Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 1456, USA
    Antimicrob Agents Chemother 53:2654-6. 2009
    ..Iron chelation alone or combined with antifungal drugs may be useful for prevention and treatment of mycosis...
  54. ncbi Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial
    Aurelio Maggio
    U O C Ematologia II con Talassemia, A O V Cervello, Palermo, Italy
    Br J Haematol 145:245-54. 2009
    ....
  55. ncbi The labile iron pool in human erythroid cells
    Eugenia Prus
    Department of Haematology, Hadassah Hebrew University Medical Centre, Jerusalem, Israel
    Br J Haematol 142:301-7. 2008
    ..The methodology presented might be useful for evaluating the LIP in various diseases and for studying the efficacy of iron-chelators...
  56. ncbi Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia
    Daniel Velasco-Sánchez
    Cardiology Department, Sant Joan de Déu Hospital, University of Barcelona, Esplugues, Spain
    Cerebellum 10:1-8. 2011
    ..Heart hypertrophy parameters and iron deposits in dentate nucleus improved significantly. Combined therapy was well tolerated with mild side effects, apart from the risk of neutropenia and progressive reduction of plasma iron parameters...
  57. ncbi Deferasirox decreases age-associated iron accumulation in the aging F344XBN rat heart and liver
    Ravi Kumar Arvapalli
    Department of Biological Sciences, Marshall University, Huntington, WV 25755, USA
    Cardiovasc Toxicol 10:108-16. 2010
    ..05). Taken together, these data suggest that deferasirox may be effective in diminishing age-associated iron accumulation and cardiac apoptosis in the F344XBN rat model...
  58. ncbi Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies
    Aurelio Maggio
    U O C Ematologia II con Talassemia, A O V Cervello, Palermo, Italy
    Blood Cells Mol Dis 42:247-51. 2009
    ..013). In conclusion, the results of this study show that the risk factors for predicting mortality in patients with thalassemia major are deferoxamine-treatment, complications, and the interaction effect of sex and age...
  59. ncbi Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study
    Norbert Gattermann
    Heinrich Heine University, Dusseldorf, Germany
    Leuk Res 34:1143-50. 2010
    ..0001). This large dataset prospectively confirms the efficacy and well characterizes the safety profile of deferasirox in MDS...
  60. ncbi Update on iron chelators in thalassemia
    Ellis J Neufeld
    Children s Hospital Boston, Dana Farber Cancer Institute, and Harvard Medical School, Boston, MA 02115, USA
    Hematology Am Soc Hematol Educ Program 2010:451-5. 2010
    ....
  61. ncbi Iron chelation therapy in MDS: what have we learnt recently?
    Mathias Schmid
    University of Ulm, Ulm, Germany
    Blood Rev 23:S21-5. 2009
    ..Unlike other iron chelators, deferasirox also appears to inhibit the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) pathway in MDS blast cells, which may lead to additional beneficial effects...
  62. ncbi Recent developments in iron chelation therapy
    H Cario
    Klinik fur Kinder und Jugendmedizin, Universitatsklinikum Ulm, Eythstrasse 24, 89075 Ulm
    Klin Padiatr 219:158-65. 2007
    ..This will allow a highly effective, individually tailored treatment hopefully leading to a fundamental improvement of patients' life expectancy and quality...
  63. ncbi Pharmacokinetics, distribution, metabolism, and excretion of deferasirox and its iron complex in rats
    Gerard J M Bruin
    Novartis Pharma AG, Drug Metabolism and Pharmacokinetics, Novartis Campus, Basel, Switzerland
    Drug Metab Dispos 36:2523-38. 2008
    ..Two hydroxylated metabolites (M1 and M2) were administered to rats and were shown not to contribute substantially to iron elimination in vivo...
  64. ncbi Siderocalin (Lcn 2) also binds carboxymycobactins, potentially defending against mycobacterial infections through iron sequestration
    Margaret A Holmes
    Division of Basic Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, Washington 98109, USA
    Structure 13:29-41. 2005
    ..tuberculosis: carboxymycobactins. Siderocalin employs a degenerate recognition mechanism to cross react with these dissimilar types of siderophores, broadening the potential utility of this innate immune defense...
  65. ncbi Selective iron chelation in Friedreich ataxia: biologic and clinical implications
    Nathalie Boddaert
    Pediatric Radiology Unit, Institut National de la Sante et de la Recherche Medicale, Hopital Necker Enfants Malades, université Paris V René Descartes, Paris, France
    Blood 110:401-8. 2007
    ..The use of moderate chelation for relocating iron from areas of deposition to areas of deprivation has clinical implications for various neurodegenerative and hematologic disorders...
  66. ncbi Acute renal failure and Fanconi syndrome due to deferasirox
    Steven Grangé
    Nephrology Department, Rouen University Hospital, 1 Avenue de Germont, 76031 Rouen Cedex, Rouen, France
    Nephrol Dial Transplant 25:2376-8. 2010
    ..This case highlights the importance of a careful monitoring of kidney function, markers of proximal tubulopathy and ferritinaemia in patients receiving deferasirox...
  67. ncbi Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia
    John B Porter
    Department of Haematology, University College London, 98 Chenies Mews, London WC1E 6HX, UK
    Best Pract Res Clin Haematol 15:329-68. 2002
    ..The value of monitoring to decrease morbidity from iron overload is also discussed, particularly with reference to the estimation of iron deposition in the pituitary...
  68. ncbi Controversies surrounding iron chelation therapy for MDS
    Heather A Leitch
    Division of Hematology, St Paul s Hospital, University of British Columbia, Vancouver, BC, Canada
    Blood Rev 25:17-31. 2011
    ..In this paper, data on the impact of IOL in MDS and SCT, possible mechanisms of iron toxicity such as oxidative stress, and the impact of lowering iron on organ function and survival are reviewed...
  69. ncbi Lifetime cost-utility analyses of deferasirox in beta-thalassaemia patients with chronic iron overload: a UK perspective
    Jonathan Karnon
    University of Adelaide, Adelaide, Australia
    Clin Drug Investig 32:805-15. 2012
    ....
  70. ncbi Novel "hybrid" iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells
    David B Lovejoy
    Heart Research Institute, The Iron Metabolism and Chelation Group, Camperdown, Sydney, New South Wales, Australia
    Blood 100:666-76. 2002
    ..These studies support the further development of these chelators as antiproliferative agents...
  71. ncbi Improvement in hematopoiesis after iron chelation therapy with deferasirox in patients with aplastic anemia
    Sung Eun Lee
    Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul St Mary s Hospital, College of Medicine, Catholic University of Korea, Seoul, Korea
    Acta Haematol 129:72-7. 2013
    ..Further long-term studies in larger patient cohorts are needed to clarify the effect of the restoration of hematopoiesis after iron chelation therapy...
  72. pmc Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues
    Raymond J Bergeron
    Department of Medicinal Chemistry, University of Florida, Gainesville, Florida 32610 0485, USA
    J Med Chem 51:3913-23. 2008
    ..i.d.), there was serious proximal tubule damage versus 474 micromol/kg/day once daily (s.i.d.). With 2 and 3, in iron-overloaded and/or non-iron-loaded rodents, kidney histopathologies remained normal...
  73. pmc Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction
    Mark A Tanner
    Cardiovascular Magnetic Resonance Unit, Royal Brompton Hospital, London, UK
    J Cardiovasc Magn Reson 10:12. 2008
    ..Combined chelation therapy with deferiprone and deferoxamine is effective for moderate myocardial siderosis, but has not been prospectively examined in severe myocardial siderosis...
  74. ncbi Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine
    Caterina Borgna-Pignatti
    Department of Pediatrics, University of Ferrara
    Haematologica 89:1187-93. 2004
    ..The interactions between gender, birth cohort, complications, and ferritin on survival and complications were analyzed...
  75. ncbi Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes
    Peter L Greenberg
    Division of Hematology, Stanford University Cancer Center, Stanford, CA 94305, USA
    Leuk Res 34:1560-5. 2010
    ....
  76. ncbi Ascorbate status modulates reticuloendothelial iron stores and response to deferasirox iron chelation in ascorbate-deficient rats
    Casey Brewer
    Division of Pediatric Cardiology, Children s Hospital Los Angeles, Los Angeles, CA 90027 0034, USA
    Exp Hematol 40:820-7. 2012
    ..Our findings suggest that ascorbate status should be probed in patients with unsatisfactory response to DFX...
  77. ncbi Anti-tumor and radiosensitization activities of the iron chelator HDp44mT are mediated by effects on intracellular redox status
    Junqiang Tian
    Department of Radiation Oncology, Stanford University, Stanford, CA 94305, USA
    Cancer Lett 298:231-7. 2010
    ..Interestingly, this radiosensitizing effect was observed under aerobic and, to a larger extent, hypoxic conditions, suggesting its potential utility as a radiosensitizer for some radioresistant tumors...
  78. ncbi Effect on ribonucleotide reductase of novel lipophilic iron chelators: the desferri-exochelins
    Yvonne K Hodges
    University of Colorado, Health Sciences Center, Department of Medicine, Division of Cardiology, Box B130, 4200 E 9th Ave, Denver, CO 80262, USA
    Biochem Biophys Res Commun 315:595-8. 2004
    ..However, because of its lipid-solubility and high binding affinity, desferri-exochelin is able to enter cells rapidly and access intracellular iron, while deferoxamine has limited capacity to cross the cell membrane...
  79. ncbi Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators
    Annita Kolnagou
    Postgraduate Research Institute of Science, Technology, Environment and Medicine, Limassol, Cyprus
    Hemoglobin 30:239-49. 2006
    ..The ICOC combination therapy protocol appears to be the most effective and least cumbersome form of chelation treatment for the rapid clearance of excess iron from the heart...
  80. ncbi Elevated serum ferritin in patients with a myelodysplastic syndrome: how much of a problem?
    Richard Stone
    Am J Hematol 83:609-10. 2008
  81. ncbi Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements
    Angel F Remacha
    Hematology Department, Centro Hospitalario de Toledo, Avenida Barber, 30, 45004, Toledo, Spain
    Ann Hematol 89:147-54. 2010
    ..In conclusion, most low-risk transfusion-dependent MDS patients develop IO, but only a minority receives a minimally effective and timely iron chelation therapy...
  82. ncbi Iron chelation adherence to deferoxamine and deferasirox in thalassemia
    Felicia Trachtenberg
    New England Research Institutes, 9 Galen Street, Watertown, MA 02472, USA
    Am J Hematol 86:433-6. 2011
    ..As adherence to deferoxamine is higher than previously reported, it appears beneficial for patients to have a choice in chelators...
  83. ncbi Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells
    Gabriela Link
    Department of Human Nutrition and Metabolism, Hebrew University Hadassah Medical School, Jerusalem, Israel
    Blood 101:4172-9. 2003
    ..These findings provide a rationale for the combined, simultaneous use of iron-chelating drugs and may have useful, practical implications for designing novel strategies of iron chelation therapy...
  84. ncbi Protection against hydrogen peroxide-mediated cytotoxicity in Friedreich's ataxia fibroblasts using novel iron chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone class
    C K Lim
    Iron Metabolism and Chelation Program, Department of Pathology, University of Sydney, Sydney, New South Wales 2006, Australia
    Mol Pharmacol 74:225-35. 2008
    ..These findings further indicate the potential of PCTH for treatment of iron overload...
  85. ncbi The iron complex of Dp44mT is redox-active and induces hydroxyl radical formation: an EPR study
    Patric J Jansson
    Department of Pathology and Bosch Institute, University of Sydney, Sydney, NSW 2006, Australia
    J Inorg Biochem 104:1224-8. 2010
    ..We discuss the relevance of the redox activity to the biological effects of Dp44mT...
  86. ncbi Iron chelator-inducible expression system for Escherichia coli
    Jae Myung Lim
    Omics and Integration Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 305 333, Korea
    J Microbiol Biotechnol 18:1357-63. 2008
    ..Since the newly developed iron chelator-inducible expression system is efficient and cost-effective, it has wide applications in recombinant protein production...
  87. ncbi Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy
    Annita Kolnagou
    Postgraduate Research Institute of Science, Technology, Environment and Medicine, Limassol, Cyprus
    Eur J Haematol 85:430-8. 2010
    ..New chelating drug protocols are necessary to treat completely transfusional iron overload and eliminate associated toxicity. Appropriate deferiprone/deferoxamine combinations could achieve this goal...
  88. ncbi Clinical efficacy and safety evaluation of tailoring iron chelation practice in thalassaemia patients from Asia-Pacific: a subanalysis of the EPIC study of deferasirox
    Vip Viprakasit
    Haematology Oncology Division, Department of Paediatrics and Thalassaemia Center, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
    Int J Hematol 93:319-28. 2011
    ..Our analysis confirms that, with appropriate adjustment of dose, deferasirox can be clinically effective across different regions, with manageable side effects...
  89. ncbi Chelation of iron within the erythrocytic Plasmodium falciparum parasite by iron chelators
    M Loyevsky
    Department of Medicine, The George Washington University Medical Center, Washington, DC 20037, USA
    Mol Biochem Parasitol 101:43-59. 1999
    ....
  90. ncbi Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies)
    Christian Rose
    Service d Onco Hématologie, Hopital Saint Vincent de Paul, Universite catholique de Lille, Lille, France
    Leuk Res 34:864-70. 2010
    ..Iron chelation therapy (CT) improves survival in thalassemia major but its beneficial effects on survival in MDS patients remain uncertain...
  91. pmc Desferrithiocin analogue iron chelators: iron clearing efficiency, tissue distribution, and renal toxicity
    Raymond J Bergeron
    Department of Medicinal Chemistry, University of Florida, JHMHC, Box 100485, Gainesville, FL 32610 0485, USA
    Biometals 24:239-58. 2011
    ..Overall, the results suggest that 3 would be a far superior clinical candidate to 9...
  92. ncbi Relationship of magnetic resonance imaging estimation of myocardial iron to left ventricular systolic and diastolic function in thalassemia
    Benedetta Leonardi
    Department of Cardiology, Children s Hospital Boston, Department of Pediatrics, Harvard Medical School, Boston, Massachusetts 02115, USA
    JACC Cardiovasc Imaging 1:572-8. 2008
    ..We sought to evaluate whether echocardiographic diastolic function indices correlate with myocardial iron and systolic function in patients with transfusion-dependent thalassemia (TDT) who are at risk for cardiomyopathy...
  93. pmc Relationship between labile plasma iron, liver iron concentration and cardiac response in a deferasirox monotherapy trial
    John C Wood
    Children s Hospital of Los Angeles, Los Angeles CA 90027, USA
    Haematologica 96:1055-8. 2011
    ..Persistently increased labile plasma iron predicts cardiac non-response to deferasirox but labile plasma iron suppression does not guarantee favorable cardiac outcome. Study registered at www.clinicaltrials.gov (NCT00447694)...
  94. ncbi Downregulation of p38 kinase pathway by cAMP response element-binding protein protects HL-60 cells from iron chelator-induced apoptosis
    Suck Chei Choi
    Digestive Disease Research Institute, Wonkwang University School of Medicine, Iksan, Chonbuk, South Korea
    Free Radic Biol Med 35:1171-84. 2003
    ..Collectively, these results demonstrate that cAMP-dependent CREB activation plays an important role in protecting HL-60 cells from iron chelator-induced apoptosis, presumably through downregulation of p38 kinase...
  95. ncbi Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state
    Felix Waldmeier
    Novartis Institutes for BioMedical Research Drug Metabolism and Pharmacokinetics, Novartis Campus, WSJ 210 4 20, Postfach, CH 4056 Basel, Switzerland
    Drug Metab Dispos 38:808-16. 2010
    ..Direct and indirect evidence indicates that the main pathway of deferasirox metabolism is via glucuronidation to metabolites M3 (acyl glucuronide) and M6 (2-O-glucuronide)...
  96. ncbi Role of iron in inducing oxidative stress in thalassemia: Can it be prevented by inhibition of absorption and by antioxidants?
    Eliezer A Rachmilewitz
    Department of Hematology, The Edith Wolfson Medical Center, P O Box 5, 58100 Holon, Israel
    Ann N Y Acad Sci 1054:118-23. 2005
    ..Treatment with combination of antioxidants such as N-acetylcysteine for proteins and vitamin E for lipids in addition to iron chelators could neutralize the deleterious effects of ROS and monitored by quantitation of LPI...
  97. ncbi Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders
    Emanuele Angelucci
    Hematology Department and BMT Unit, Cancer Center Armando Businco, viale Edward Jenner, 09121 Cagliari, Italy
    Haematologica 93:741-52. 2008
    ....
  98. pmc Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias
    Maria Domenica Cappellini
    Universita di Milano, Policlinico Foundation IRCCS, Milan, Italy
    Haematologica 95:557-66. 2010
    ....
  99. ncbi Deferiprone chelation therapy for thalassemia major
    R Galanello
    Dipartimento di Scienze Biomediche e Biotecnologie, Ospedale Regionale Microcitemie, Azienda Sanitaria Locale 8, Universita di Cagliari, Cagliari, Italia
    Acta Haematol 122:155-64. 2009
    ..More common but less serious side effects are gastrointestinal symptoms, arthralgia, zinc deficiency, and fluctuating transaminase levels...
  100. ncbi Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial
    Jong Wook Lee
    Division of Hematology, Department of Internal Medicine, Seoul St Mary s Hospital, The Catholic University of Korea, Seoul, South Korea
    Blood 116:2448-54. 2010
    ..This prospective dataset confirms the efficacy and well characterizes the tolerability profile of deferasirox in a large population of patients with aplastic anemia. This study was registered at www.clinicaltrials.gov as #NCT00171821...
  101. pmc Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study
    John Porter
    University College London, London, UK
    Eur J Haematol 80:168-76. 2008
    ..Dosage was determined by baseline liver iron concentration (LIC)...

Research Grants62

  1. Hepcidin Replacement Therapy for Iron Overload Disorders
    James W Larrick; Fiscal Year: 2013
    ..Hepcidin-Fc is expected to have activity equal to or better than hepcidin and have favorable pharmacokinetics with increased plasma half-life permitting once monthly administration. ..
  2. IRON CHELATORS PREDICATED ON DESFERRITHIOCIN
    RAYMOND JOSEPH BERGERON; Fiscal Year: 2013
    ..iron chelator (siderophore) isolated from Streptomyces antibioticus, is one of the most orally effective iron chelating agents yet identified but renal toxicity precludes its clinical use...
  3. CULTURED CARDIAC MYOCYTES--A MODEL OF IRON OVERLOAD
    Chaim Hershko; Fiscal Year: 1991
    ..help in clarifying the pathogenesis of mypocardial disease in iron overload, the manner in which hypoxia, iron chelating agents and antioxidants may modify or prevent iron-induced damage to the heart, and may be useful in developing ..
  4. ACCELERATING IRON CHELATION FROM SERUM TRANSFERRIN
    WESLEY HARRIS; Fiscal Year: 2004
    ..low molecular weight ligands tends to be very slow, which severely restricts the ability of therapeutic iron chelating agents to target this readily accessible iron pool...
  5. MICROBIAL IRON TRANSPORT
    BENJAMIN BYERS; Fiscal Year: 1980
    Microbial iron transport is under study. Many microorganisms excrete high affinity iron chelating agents which function as iron transport cofactors (siderophores)...
  6. CARDIOMYOPATHY OF IRON OVERLOAD--FIRST ANIMAL MODEL
    George Miller; Fiscal Year: 1992
    ....
  7. DESIGN AND CLINICAL ASSESSMENT OF PYRIDINONE CHELATORS
    Robert Hider; Fiscal Year: 1992
    This project seeks to develop oral iron chelating agents for the treatment of transfusional iron overload based on the promising results of the previous work on the 3-hydroxypyridin-4-ones...
  8. THALASSEMIAS, HEMOGLOBINOPATHIES AND RELATED PROBLEMS
    Prawase Wasi; Fiscal Year: 1991
    ..Dynamics of the complex relationship between the erythron and iron kinetics is studied counter. Evaluation of new oral iron chelating agents in thalassemia will be carried out before recommendation for their use in general.
  9. MODELING OF MIXED LIGAND THERAPY FOR IRON OVERLOAD
    Robert Hider; Fiscal Year: 2002
    ..We aim to define the principles and potential candidates for optimal mixed ligand therapy for iron overload. ..
  10. Cardiac Function and Cardiac iron (T2*) in Thalassemia
    John Wood; Fiscal Year: 2007
    ..These studies will provide the necessary groundwork for longitudinal studies of cardiac iron load on cardiac performance in thalassemia patients. ..
  11. IRON CHELATORS PREDICATED ON DESFERRITHIOCIN
    RAYMOND BERGERON; Fiscal Year: 2004
    ....
  12. Desferrithiocin Analogue Actinide Decorporation Agents
    RAYMOND BERGERON; Fiscal Year: 2008
    ..abstract_text> ..
  13. CARDIOPROTECTIVE EFFECT--NEW CHELATORS FOR THALASSEMIA
    Chaim Hershko; Fiscal Year: 2001
    ..abstract_text> ..
  14. E/BETA THALASSEMIA--NATURAL HISTORY & RESPONSE TO CHEMO
    Elliott Vichinsky; Fiscal Year: 2002
    ..In summary, if this study is successful, it will change the approach to Hb E/B worldwide and result in improved quality of life and decreased mortality. (End of Abstract) ..
  15. Modulation of Iron Deposition in SCD and Other Hemoglobinopathies
    ELLIOTT P contact VICHINSKY; Fiscal Year: 2010
    ....
  16. Free Iron, Estrogen and Postmenopausal Osteoporosis
    Gang Liu; Fiscal Year: 2002
    ..Moreover, this new approach will permit the reevaluation of the role of estrogen and will expedite the development of novel pharmaceutical agents for the prevention or treatment of osteoporosis. ..
  17. Eighth Cooley's Anemia Symposium
    Elliott Vichinsky; Fiscal Year: 2005
    ....
  18. Nanoparticle Brain Delivery of Iron Chelators for AD
    Gang Liu; Fiscal Year: 2004
    ..Overall, this: exploratory: study may open the door for the use of iron chelator nanoparticle systems to target diseased organs for iron chelation therapy. ..
  19. ERYTHROCYTAPHERESIS TO LOWER IRON LOADING IN THALASSEMIA
    Alan Cohen; Fiscal Year: 2002
    ....
  20. Novel Antifungal Strategies for Lethal Mucormycosis
    Ashraf Ibrahim; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  21. Treatment of Fungal Infections with ATAK Cells
    Ashraf Ibrahim; Fiscal Year: 2004
    ..Furthermore, the genetic construct targeting ATAK cells to Candida can easily be adapted to any other pathogen against which a MAb has been raised. ..
  22. Adrenergic Antagonism During Murine Candidiasis
    Brad Spellberg; Fiscal Year: 2008
    ..For these reasons, the potential for adrenergic antagonism to act as an effective immunotherapy is highly meritorious of investigation in this training application. ..
  23. MECHANISMS OF RENAL TUBULAR EPITHELIAL CELL INJURY
    Sudhir Shah; Fiscal Year: 2005
    ..abstract_text> ..
  24. Role of reactive oxygen species in synaptic transmission
    Michael Levy; Fiscal Year: 2002
    ..In addition to characterizing the VDAC knockout mouse, I will determine the downstream effectors involved in ROS signaling during synaptic transmission. ..
  25. Innate Effectors of rAls3p-N Anti-Candida Vaccine
    Brad J Spellberg; Fiscal Year: 2010
    ..PNS 398/2590 (Rev. 11/07) Page - Continuation Format Page ..
  26. Antioxidant Interaction of Selenium and Vitamins C & E
    James May; Fiscal Year: 2008
    ..Using this approach, it will be possible to relate the crucial, mitochondrial functions of selenium and vitamins C and E to the antioxidant defenses of the whole animal. ..
  27. Elucidating the properties of low-molecular-weight chromuim-binding substance
    John Vincent; Fiscal Year: 2007
    ..The approach will employ two advancing methodologies in mass spectrometry: electrospray ionization Fourier transform ion cyclotron resonance (ESI/FT-ICR) and matrix-assisted laser desorption ionization time-of-flight (MALDI/TOF). ..
  28. Intestinal ferroportin 1 expression and iron absorption
    Kwo Yih Yeh; Fiscal Year: 2009
    ..The results should reveal mechanisms involved in the regulation and function of FPT1 and extend our understanding of intestinal iron absorption and body iron homeostatic regulation. ..
  29. Investigations of the Bioinorganic Chemistry of Iron: New Siderophores
    Alison Butler; Fiscal Year: 2009
    ..abstract_text> ..
  30. Regulation of APP Degradation and ABeta Secretion
    David Schubert; Fiscal Year: 2008
    ..In addition, understanding how cells regulate the degradation of proteins is critical to the study of a wide range of diseases, particularly those in the nervous system that are characterized by the intracellular protein accumulation. ..
  31. Etiology, Stem Cell Biology and Therapy of Anemia in the Elderly
    Stanley L Schrier; Fiscal Year: 2010
    ....
  32. Effect of Inducible Antioxidants on Hemoglobin Toxicity
    Raymond F Regan; Fiscal Year: 2010
    ..The ultimate goal is to reduce brain injury in tissue surrounding a blood clot, and to thereby improve the likelihood of survival and return to an independent, productive life. ..
  33. Chronological Age-Dependent Genomic Instability in Yeast
    Valter D Longo; Fiscal Year: 2010
    ..Thus, chronologically aging S. cerevisiae can serve as a model to identify genes that regulate genomic instability and understand the mechanisms responsible for age-dependent DNA mutations and cancer in mammals. ..
  34. UROLITHIASIS AND PEROXIDATIVE INJURY
    Sivagnanam Thamilselvan; Fiscal Year: 2008
    ..These studies will provide valuable information on the importance of antioxidants and, whether antioxidants offer promise as a therapeutic agent for recurrent stone formers. ..
  35. Oxidative Stress Na Channel Gating and Arrhythmias
    L Roberts; Fiscal Year: 2007
    ..These studies should improve our understanding of the mechanisms linking oxidant injury and arrhythmias and have the potential to identify novel antiarrhythmic therapeutic strategies. [unreadable] [unreadable]..
  36. PROTECTIVE ROLE OF APOPTOSIS IN ASBESTOS PLEURAL INJURY
    V Broaddus; Fiscal Year: 2001
    ..These studies should provide important information about the mechanisms by which asbestos induces apoptosis in mesothelial cells and the role of asbestos-induced apoptosis in asbestos-induced pathology. ..
  37. DEVELOPMENTAL HEMATO-ENDOTHELIAL BIOLOGY OF P1H12
    Robert Hebbel; Fiscal Year: 2002
    ..These studies represent a first step towards defining the role of P1H12 in embryology, with an emphasis on hematopoiesis and vasculogenesis (as rationalized by exciting preliminary data). ..
  38. CARDIAC DISEASE IN COOLEYS ANEMIA--MOLE AND CLIN STUDIES
    Gary Brittenham; Fiscal Year: 2002
    ....
  39. ROLE OF 02 RADICALS AND IRON IN ASBESTOS-INDUCED CANCER
    ANN AUST; Fiscal Year: 2003
    ..To determine how iron and GSH modulate the activity of Src kinase, monobromobimane labeling of regulatory cysteines will be monitored. ..
  40. Antioxidant Functions of Lipoic Acid
    James May; Fiscal Year: 2004
    ..Despite the widespread use of lipoic acid, these studies are necessary to establish the biological basis and rationale for the clinical use of the agent. ..
  41. Respirable ciprofloxacin aerosol for inhaled anthrax
    Brooks Hybertson; Fiscal Year: 2004
    ..Our overall goal is to create a new tool for targeted treatment or prophylaxis for victims of anthrax spore inhalation. ..
  42. PEDIATRIC HEMATOLOGY RESEARCH TRAINING PROGRAM
    Gary Brittenham; Fiscal Year: 2005
    ..End of Abstract) ..
  43. Pathogenesis of severe malarial anemia in Thailand
    Gary Brittenham; Fiscal Year: 2005
    ..abstract_text> ..
  44. Cell Cycle Controlling Genes in Adult Acute Lymphoma
    Guillermo Garcia Manero; Fiscal Year: 2005
    ..abstract_text> ..
  45. Pathophysiology of thiamine-responsive anemia syndrome
    Ellis Neufeld; Fiscal Year: 2006
    ....
  46. Amplification of TRIAL-Indcued Apoptosis in Mesothelioma
    V Broaddus; Fiscal Year: 2006
    ..the mechanisms of amplification of TRAIL-induced apoptosis can provide insight into the means by which malignant cells evade apoptosis and ways to bypass those sites of resistance and thereby improve treatment strategies ..
  47. Magnetic Resonance Measurement of Heart and Liver Iron
    Gary Brittenham; Fiscal Year: 2006
    ..S. and worldwide. ..
  48. Redox Sensitive Proteins in Aging and Neurodegeneration
    David Schubert; Fiscal Year: 2006
    ..These proteins, in turn, will be used as targets for the identification of potentially therapeutic antioxidants that could be useful in preventing age-and disease-associated damage to the CNS. ..
  49. Development and Testing of a Novel Neuroprotective Drug
    David Schubert; Fiscal Year: 2006
    ..The results from these studies will determine the therapeutic potential of this novel compound. [unreadable] [unreadable]..
  50. ENDOTHELIAL CELL OUTGROWTH FROM BLOOD
    Robert Hebbel; Fiscal Year: 2001
    ..abstract_text> ..